Status:
COMPLETED
Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus
Lead Sponsor:
Case Comprehensive Cancer Center
Conditions:
Short Segment Barrett's Esophagus
Long Segment Barrett's Esophagus
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This study is being conducted to determine if vitamin D supplementation increases the level of a protein that may be involved in decreasing the risk of esophageal cancer in patients with Barrett's eso...
Detailed Description
28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor). The purpose of the run-in phase i...
Eligibility Criteria
Inclusion
- Known diagnosis of short-segment or long-segment Barrett's esophagus as previously made by upper endoscopy showing salmon-colored distal esophageal mucosa and biopsies revealing intestinal metaplasia with goblet cells. Potential study subjects may be contacted by mailings or phone calls or may be approached in clinic. Additionally, potential study subjects may be approached using a web-based recruitment tool. Informed consent will be obtained by a research coordinator or study investigator.
- Subjects may be taking calcium supplements or have previous history of hypercalcemia
- Subjects may have diabetes mellitus
- Subjects may have a history of prior malignancy except for esophageal adenocarcinoma
- Willing to donate 90 mL of blood and endoscopic mucosal biopsies for research
- The following additional inclusion criteria apply for patients in the Vitamin D/metformin sub-arm of the low grade dysplasia/no dysplasia arm:
- At least 2 cm circumferential Barrett's esophagus segment length (C2M2 by Prague C \& M criteria)
- Normal renal function (defined as creatinine within normal institutional limits)
Exclusion
- Pregnancy
- Known chronic liver disease (Child's B cirrhosis)
- Known chronic kidney disease (creatinine ≥ 3.0)
- Esophageal adenocarcinoma
- Allergic reaction to omeprazole
- Allergic reaction to vitamin D
- Unable or unwilling to provide informed consent
- Known hypercalcemia
- Previous ablative therapy for Barrett's esophagus
- Patients on a stable (\>/=4 week duration) dose of \>2000 IU/day (or equivalent) of vitamin D supplementation
- The following additional exclusion criteria apply for patients in the Vitamin D/metformin sub-arm of the no dysplasia/low grade dysplasia arm:
- Allergic reaction to metformin
- History of diabetes mellitus
- History of lactic acidosis
- History of B12 deficiency
- Participants may not be using metformin, cimetidine (Tagamet) furosemide (Lasix), nifedipine (Cardizem), or any other drug contraindicated for use with metformin.
- Treatment with other oral hypoglycemic agents
- Participants planning to undergo elective radiologic studies involving intravascular administration of iodinated contrast materials.
- Known chronic kidney disease with creatinine greater than normal institutional limits
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01465113
Start Date
May 1 2010
End Date
February 1 2016
Last Update
March 10 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Ahuja Medical Center
Beachwood, Ohio, United States, 44122
2
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
3
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44195